Executive Interviews
EXECUTIVE INTERVIEW - Petros Pharmaceuticals & Self-Care: Expanding Access to Rx Products Through a Tech-Powered OTC Pathway
Fady Boctor, President and Chief Commercial Officer at Petros Pharmaceuticals, discusses the process of taking a product from Rx-to-OTC, the benefits and challenges of the process, and the future of the marketplace.
DRUG DEVELOPMENT EXECUTIVE - Thermo Fisher Scientific: What to Expect From the Next Wave of RNA-Based Therapeutics
Dr. Dale Patterson, Vice President and General Manager, Molecular Biology at Thermo Fisher Scientific, delves into the world of RNA therapies and understand their next act beyond COVID-19.
EXECUTIVE INTERVIEW - How Resilience Is Bringing Forward Thinking to Disrupt the Biomanufacturing Landscape to Increase Access to Medicines
Syed T. Husain, Chief Commercial Officer of Resilience, discusses how the company became an industry-leading service provider in less than 4 years.
EXECUTIVE INTERVIEW - Samsung Biologics: Exploring The Evolving Biopharma Landscape
Kevin Sharp, Senior VP & Head of Sales for Samsung Biologics, discusses the evolving biopharma space, exploring current challenges, and the demand for sustainable solutions.
EXECUTIVE INTERVIEW - Lonza Small Molecules: Facing Up to the Challenges of Drug Development
Jan Vertommen, Lonza’s Head of Commercial Development (Small Molecules) discusses some of the challenges facing the sector and how his company is looking to address them.
EXECUTIVE INTERVIEW - Precision NanoSystems Inc. (part of Cytiva) & SCIEX: Lipid Impurities Within mRNA-LNPs
Kerstin Pohl, Senior Manager of Cell & Gene Therapy & Nucleic Acids at SCIEX, and Scott Ripley, General Manager of Nucleic Acid Therapeutics at Cytiva, dive into the detection of a new class of impurities within mRNA drugs and the impact it has on manufacturing.
EXECUTIVE INTERVIEW - HERMES PHARMA: Reducing Risk, Speeding Development - A CDMO Model Including GCP-Sponsorship to Better Meet the Needs of Pharma Companies
Dr. Martin Koeberle, Head of Analytical Development & Stability Testing, and Dr. Bernice Wild, Head of Stability Testing and Senior QA Manager GCP, at HERMES PHARMA, discuss the challenges of developing innovative oral medicines, as well as how these new service offerings are helping meet a critical need among companies looking to bring portfolio-enhancing formulations to market.
EXECUTIVE INTERVIEW - Sever Pharma Solutions: Development & Manufacturing of High Potent Polymer-Based Dosage Forms
Tony Listro, Vice President of Technology and Site Lead for SPS’s North American site in Putnam, CT, discusses the company’s recent focus areas as well as current plans for expansion.
EXECUTIVE INTERVIEW - Tarsus Pharmaceuticals: A Journey to Establishing a New Disease Category in Eyecare & Transforming Treatment for Patients With Serious Diseases
Sesha Neervannan, PhD, Chief Operating Officer of Tarsus, discusses the company’s innovative approach to creating a new treatment category for eyelid disease and their strategic focus on advancing other treatments in their pipeline.
EXECUTIVE INTERVIEW - Jubilant HollisterStier: The Importance of Expertise in Sterile Fill Finish
Chris Preti, President of Jubilant HollisterStier, discusses how the CMO is handling increased demand for sterile fill finish and how expertise makes a difference to customer relationships and finished product quality.
EXECUTIVE INTERVIEW - Lifecore Biomedical: Emerging From Under the Radar
Darren Hieber discusses his company’s progress after his first year as Sr. Vice President of Corporate Development and Partnerships at Lifecore Biomedical.
EXECUTIVE INTERVIEW - Novadip Biosciences: Developing a New Class of Regenerative Tissue Products to Accelerate Healing of Critical Size Bone Defects, Trauma & Spinal Problems
Denis Dufrane, MD, PhD, Chief Executive Officer, and Founder of Novadip Biosciences, discusses his company’s innovative approach to tissue regeneration technology.
EXECUTIVE INTERVIEW - Ascendia Pharmaceuticals: Innovative Solutions to Challenging Problems
Jim Huang, PhD, CEO and Founder of Ascendia Pharmaceuticals, discusses how his company expanded its people, capabilities, and facilities to meet and exceed customer expectations from early to late-state development and how this investment allows Ascendia to continue be an expert in sophisticated formulations, as well as cGMP sterile and non-sterile clinical trial and commercial manufacturing.
EXECUTIVE INTERVIEW - PCI Pharma Services: The Global, Integrated CDMO Partner of Choice
John Ross, Senior Vice President of Development and Manufacturing at PCI Pharma Services, discusses what it means to be the partner of choice in a very dynamic industry.
EXECUTIVE INTERVIEW - ICON: Transforming Clinical Trials in a Rapidly Shifting Landscape
Ute Berger, MD, President, Development & Commercialization Solutions at ICON plc, discusses how with the acquisition of PRA in 2021, it has enhanced its value proposition and how it is transforming clinical trials in a rapidly shifting landscape.
EXECUTIVE INTERVIEW - Purple Biotech Ltd.: Developing First-In-Class Oncology Therapies
Gil Efron, Chief Executive Officer of Purple Biotech, discusses the company’s focus on identifying and developing promising molecules that may offer first-in-class approaches to treating devastating cancers with large unmet medical needs.
EXECUTIVE INTERVIEW - TC BioPharm: Developing Platform Allogeneic Gamma-Delta T Cell Therapies for Cancer
Bryan Kobel, CEO of TC BioPharm, discusses his company’s upcoming plans, therapeutic clinical trials, and the biotech landscape.
EXECUTIVE INTERVIEW - Ajinomoto Bio-Pharma Services: Giving You the Power to Make
Dr. Nobu Shimba, CEO and President of Ajinomoto Bio-Pharma Services US, discusses the company’s recent areas of focus as well as current plans for expansions.
EXECUTIVE INTERVIEW - Alcami: Unlocking the Potential of Transformative Medicine for 40 Years
Mike Babics, Vice President, Parenteral Services at Alcami, discusses the company’s recent expansions in formulation and analytical development, manufacturing, release testing, and biostorage of clinical and commercial drug products for both solid dosage and parenteral products.
EXECUTIVE INTERVIEW - Owen Mumford & Stevanato Group: Collaborating to Produce Aidaptus® Auto-injector
Michael Earl, Director of Pharmaceutical Services at Owen Mumford, and Steven Kaufman, Vice President for Drug Delivery Systems at Stevanato Group, discuss their collaboration in producing the innovative Aidaptus auto-injector.
